News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
289–324
Matches
405
Sources here
17
Companies here
14
Search results Stored financial headlines

Active search

405 matching headlines

Ticker or company: ROMMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Planned sale of 10,000 ANF Class A shares (NYSE: ANF) disclosed

A holder of Abercrombie & Fitch Co. (NYSE: ANF) Class A shares plans to sell up to 10,000 shares through Fidelity Brokerage Services LLC. The proposed sale, valued at $1,000,000.00, is scheduled for July 16, 2026. These shares were acquired as compensation through restricted …

ANF main company
Sharemaestro market context Trend signal started 52 weeks +9.8% · Next-week setup positive 61.1% ANF stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN)

Guggenheim reiterated its "Buy" rating for ProMIS Neurosciences (PMN) with a $35.00 price target, following a previous "Buy" rating from Roth MKM. Despite a quarterly GAAP net loss of $8.24 million, corporate insider sentiment is positive, with increased insider buying, including a recent purchase …

PMN main company
Sharemaestro market context Price above Trend Line 52 weeks +10.9% · Next-week setup negative 43.5% PMN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18

H.C. Wainwright has reiterated its Buy rating for ProMIS Neurosciences (PMN.US) and maintained a target price of $18. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

PMN main company
Sharemaestro market context Price above Trend Line 52 weeks +10.9% · Next-week setup negative 43.5% PMN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Grupo Aeromexico (AERO) Q2 2026 earnings summary

Grupo Aeromexico (AERO) reported a record second-quarter revenue of $1.5 billion in Q2 2026, driven by strong demand and disciplined capacity management, despite rising fuel costs. The company maintained profitability within guidance, with an EBIT margin of 5%, and ended the quarter with strong …

AERO main company
Sharemaestro market context Price below Trend Line 41 weeks -18.8% AERO stored weekly price path from 7 Nov 2025 to 14 Aug 2026

Grupo Aeroméxico (AERO) earnings arrive with a 37-cent loss estimate

The July 13 report matters because the airline’s short-term share performance has weakened while its broader weekly context remains mixed.

AERO main company
Sharemaestro market context Price below Trend Line 41 weeks -18.8% AERO stored weekly price path from 7 Nov 2025 to 14 Aug 2026

Grupo Aeroméxico (AERO) faces earnings after a short weekly setback

The July 13 report arrives with longer-period gains still intact, but the weekly trend signal is inactive and Market Dynamics show pressure.

AERO main company
Sharemaestro market context Price below Trend Line 41 weeks -18.8% AERO stored weekly price path from 7 Nov 2025 to 14 Aug 2026

Grupo Aeroméxico, S.A.B. de C.V. (AERO) volume doubles before July 13 earnings

The airline stock has pulled back over the latest week, but its four-week and twelve-week returns remain positive heading into results.

AERO main company
Sharemaestro market context Price below Trend Line 41 weeks -18.8% AERO stored weekly price path from 7 Nov 2025 to 14 Aug 2026

Grupo Aeroméxico, S.A.B. de C.V carries 28.3% 12-week gain into earnings watch (AERO)

The airline’s latest weekly close sits above market-data fair value, while volume and trend readings make the setup less forceful.

AERO main company
Sharemaestro market context Price below Trend Line 41 weeks -18.8% AERO stored weekly price path from 7 Nov 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context